Want to see SG:569 full AI Analyst Report?
569 Stock Chart & Stats
S$0.08
S$0.00(0.00%)
At close: 4:00 PM EDT
S$0.08
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.07 - S$0.10
Previous CloseN/A
Volume4.90K
Average Volume (3M)97.25K
Market Cap
S$39.35M
Enterprise ValueS$78.28M
Total Cash (Recent Filing)S$6.51M
Total Debt (Recent Filing)S$43.91M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding511,537,700
10 Day Avg. Volume66,350
30 Day Avg. Volume97,253
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.65
Price to Sales (P/S)0.39
P/FCF Ratio-7.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound (2025)A 44.7% revenue rebound in 2025 indicates demand recovery and top-line momentum that can support durable scale benefits. Sustained revenue growth over the next 2–6 months helps absorb fixed costs, improves operating leverage potential, and provides runway to restore profitability if cost controls persist.
Healthy Gross MarginsConsistently high gross margins (~51–55%) point to product-level pricing power or efficient manufacturing — structural advantages in medical devices. These margins give the company a cushion against input cost inflation and support recovery of operating profits if SG&A and overhead are managed.
Sizable Equity CushionA S$71–79m equity base provides long-term solvency strength and funding flexibility. This sizable equity buffer reduces short-term solvency risk, supports borrowing capacity, and gives management room to invest or restructure without immediate dilution, aiding multi-month strategic initiatives.
Bears Say
Weak Operating Cash GenerationOperating cash flow collapsing to ~S$0.4m and consecutive negative free cash flow in 2024–2025 signal structurally weaker cash conversion. Persistent cash shortfalls limit the company's ability to fund operations and growth internally, increasing reliance on external financing and raising execution risk over months.
Rising LeverageDebt-to-equity climbing toward ~0.58 marks a meaningful shift in capital structure and increases fixed obligations. Higher leverage reduces financial flexibility, elevates refinancing and interest-rate sensitivity, and constrains strategic optionality, making the company more vulnerable to cash-flow volatility over the medium term.
Shift To Net Losses And Negative ROEA transition from multi-year profitability to net losses and negative ROE denotes an erosion of earnings power. Sustained losses can deplete retained earnings, impair reinvestment capacity, and pressure margins and competitive positioning unless corrective actions restore operating discipline and margin recovery.
VicPlas International Ltd. News
569 FAQ
What was VicPlas International Ltd.’s price range in the past 12 months?
VicPlas International Ltd. lowest share price was S$0.07 and its highest was S$0.10 in the past 12 months.
What is VicPlas International Ltd.’s market cap?
VicPlas International Ltd.’s market cap is S$39.35M.
When is VicPlas International Ltd.’s upcoming earnings report date?
VicPlas International Ltd.’s upcoming earnings report date is Sep 25, 2026 which is in 53 days.
How were VicPlas International Ltd.’s earnings last quarter?
VicPlas International Ltd. released its earnings results on Mar 13, 2026. The company reported -S$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.007.
Is VicPlas International Ltd. overvalued?
According to Wall Street analysts VicPlas International Ltd.’s price is currently Overvalued.
Does VicPlas International Ltd. pay dividends?
VicPlas International Ltd. pays a Annually dividend of S$0.004 which represents an annual dividend yield of N/A. See more information on VicPlas International Ltd. dividends here
What is VicPlas International Ltd.’s EPS estimate?
VicPlas International Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VicPlas International Ltd. have?
VicPlas International Ltd. has 511,537,700 shares outstanding.
What happened to VicPlas International Ltd.’s price movement after its last earnings report?
VicPlas International Ltd. reported an EPS of -S$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.124%.
Which hedge fund is a major shareholder of VicPlas International Ltd.?
Currently, no hedge funds are holding shares in SG:569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VicPlas International Ltd.
Vicplas International Ltd, established in Singapore in 1993, operates as an investment holding company with key business segments in medical devices and piping systems. The company's geographical reach includes Singapore, Malaysia, the People's Republic of China, and the United Kingdom. Its piping division focuses on the manufacturing, trading, and distribution of a variety of piping solutions. These systems are utilized for diverse applications such as waste and potable water management in residential, educational, commercial, and industrial settings; conduits for underground electrical and internal building wiring; and data and signal lines for telecommunication providers. Additionally, Vicplas is engaged in the design, development, production, and assembly of both sterile and non-sterile medical devices. The company also offers specialized project design and engineering services. Vicplas International Ltd is a subsidiary of Venner Capital S.A.
Technical Analysis
Asiamedic Limited
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Alliance Healthcare Group Ltd.
―
Medinex Ltd.
―